🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 60 of 757 · Phase 3 first, then by program name

  1. GLASSIA

    Takeda Pharmaceuticals International AG

    Graft Versus Host Disease

    phase 3 mab terminated

    1 trial

  2. GLASSIA

    Takeda Pharmaceuticals International AG

    Alpha1-antitrypsin Deficiency

    phase 3 mab completed

    1 trial

  3. GLPG CAR T-cell therapy

    Lakefront Biotherapeutics NV

    Hematological Malignancies

    phase 3 gene therapy active

    1 trial

  4. GLPG0634, Jyseleca 200 mg film-coated tablets, Jyseleca 100 mg film-coated tablets

    Alfasigma S.p.A.

    Ulcerative colitis

    phase 3 small molecule active

    1 trial

  5. GLPG0634, Jyseleca 200 mg film-coated tablets, Jyseleca 100 mg film-coated tablets

    Alfasigma S.p.A.

    Juvenile idiopathic arthritis

    phase 3 small molecule active

    1 trial

  6. GLPG1690

    Lakefront Biotherapeutics NV

    Idiopathic Pulmonary Fibrosis

    phase 3 small molecule terminated

    2 trials

  7. GLUCOPHAGE 500 mg tabletki powlekane, Placebo

    Bial Portela & Companhia S.A.

    papillary thyroid carcinoma

    phase 3 small molecule active

    1 trial

  8. GLUCOTHERA PLUS

    Pharma Mar S.A.

    End-stage Kidney Disease

    phase 3 small molecule active

    1 trial

  9. GOSERELIN, RIBOCICLIB, ANASTROZOLE, LETROZOLE

    Novartis Ophthalmics Europe

    hormone receptor (HR)-positive, HER2-negative, early breast cancer (EBC).

    phase 3 small molecule active

    1 trial

  10. GS-100

    Grace Therapeutics

    NGLY1 Deficiency

    phase 3 gene therapy active

    1 trial

  11. GS-1720, Biktarvy 50 mg/200 mg/25 mg film-coated tablets, GS-4182

    Gilead Sciences International Limited

    HIV-1 Infection

    phase 3 small molecule active

    1 trial

  12. GS-4182, Biktarvy 50 mg/200 mg/25 mg film-coated tablets, GS-1720

    Gilead Sciences International Limited

    HIV-1 Infection

    phase 3 small molecule active

    1 trial

  13. GS-5245 tablets 175 mg, GS-5245 tablets 350 mg

    Gilead Sciences International Limited

    COVID-19

    phase 3 small molecule active

    1 trial

  14. GTX-102

    Ultragenyx UK Limited

    Angelman Syndrome

    phase 3 small molecule active

    4 trials

  15. GTX-102, GTX/UX Diluent and Flush Solution

    Pharma Mar S.A.

    Angelman Syndrome

    phase 3 small molecule active

    1 trial

  16. GTX-104

    Grace Therapeutics

    Aneurysmal Subarachnoid Hemorrhage (aSAH)

    phase 3 small molecule active

    1 trial

  17. GTX/UX Diluent and Flush Solution, GTX-102, ELLIOTTS B SOLUTION (buffered intrathecal electrolyte/dextrose injection)

    Pharma Mar S.A.

    Angelman Syndrome

    phase 3 small molecule active

    1 trial

  18. GW-1000-02

    Jazz Pharmaceuticals Ireland Limited

    Pain

    phase 3 small molecule completed

    3 trials

  19. GW-1000-02

    Jazz Pharmaceuticals Ireland Limited

    Multiple Sclerosis

    phase 3 small molecule completed

    4 trials

  20. GWP42003-P

    Jazz Pharmaceuticals Ireland Limited

    Tuberous Sclerosis Complex

    phase 3 small molecule completed

    2 trials

  21. GWP42003-P

    Jazz Pharmaceuticals Ireland Limited

    Infantile Spasms

    phase 3 small molecule completed

    2 trials

  22. GWP42003-P

    Jazz Pharmaceuticals Ireland Limited

    Rett Syndrome

    phase 3 small molecule terminated

    2 trials

  23. GWP42003-P

    Jazz Pharmaceuticals Ireland Limited

    Seizure in Participants With Tuberous Sclerosis Complex

    phase 3 small molecule terminated

    1 trial

  24. GWP42003-P

    Jazz Pharmaceuticals Ireland Limited

    Seizures Associated With EMAS

    phase 3 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources